Dynavax Technologies reported $173.1M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
TG Therapeutics TGTX:US USD 92K 479K
Agenus AGEN:US USD 22.46M 3.56M
Amgen AMGN:US USD 5.06B 20M
AstraZeneca AZN:LN USD 8.86B 3M
Astrazeneca AZN:US USD 8.86B 3M
Biogen BIIB:US USD 2.04B 66.1M
Biomarin Pharmaceutical BMRN:US USD 389.06M 21.62M
Bristol Myers Squibb BMY:US USD 8.86B 345M
Chimerix CMRX:US USD 32.22M 31.78M
Gilead Sciences GILD:US USD 5.65B 829M
Glaxosmithkline GSK:US GBP 5.44B 650M
Merk MRK:US USD 11.52B 1.08B
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Neurocrine Biosciences NBIX:US USD 381.8M 8.4M
Novartis NOVN:VX USD 9.18B 151M
Pfizer PFE:US USD 16.55B 2.52B
Regeneron Pharmaceuticals REGN:US USD 2.62B 58.3M
Roche Holding ROG:VX 22.73B 924M
Sarepta Therapeutics SRPT:US USD 190.32M 5.38M
Vertex Pharmaceuticals VRTX:US USD 2.04B 110.5M